Literature DB >> 29544033

Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States.

Narjeet S Khurmi1, Yu-Hui Chang2, D Eric Steidley3, Andrew L Singer4, Winston R Hewitt4, Kunam S Reddy4, Adyr A Moss4, Amit K Mathur2,4.   

Abstract

Cardiovascular disease (CVD) is a leading cause of post-liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals. Using a merged data set from the 2002-2011 Nationwide Inpatient Sample and the American Hospital Association Annual Survey, we evaluated liver transplant patients admitted primarily with myocardial infarction (MI), stroke (cerebrovascular accident [CVA]), congestive heart failure (CHF), dysrhythmias, cardiac arrest (CA), or malignant hypertension. Patient-level data include demographics, Charlson comorbidity index, and CVD diagnoses. Facility-level variables included ownership status, payer-mix, hospital resources, teaching status, and physician/nursing-to-bed ratios. We used generalized estimating equations to evaluate patient- and hospital-level factors associated with mortality. There were 4763 hospitalizations that occurred in 153 facilities (transplant hospitals, n = 80). CVD hospitalizations increased overall by 115% over the decade (P < 0.01). CVA and MI declined over time (both P < 0.05), but CHF and dysrhythmia grew significantly (both P < 0.03); a total of 19% of hospitalizations were for multiple CVD diagnoses. Transplant hospitals had lower comorbidity patients (P < 0.001) and greater resource intensity including presence of cardiac intensive care unit, interventional radiology, operating rooms, teaching status, and nursing density (all P < 0.01). Transplant and nontransplant hospitals had similar unadjusted mortality (overall, 3.9%, P = 0.55; by diagnosis, all P > 0.07). Transplant hospitals had significantly longer overall length of stay, higher total costs, and more high-cost hospitalizations (all P < 0.05). After risk adjustment, transplant hospitals were associated with higher mortality and high-cost hospitalizations. In conclusion, CVD after liver transplant is evolving and responsible for growing rates of inpatient care. Transplant hospitals are associated with poor outcomes, even after risk adjustment for patient and hospital characteristics, which may be attributable to selective referral of certain patient phenotypes but could also be related to differences in quality of care. Further study is warranted.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29544033     DOI: 10.1002/lt.25055

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  8 in total

Review 1.  PRO: Cardiac Catheterization Is the Optimal Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Brett Sadowski; Tilak Baba; Amol S Rangnekar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 2.  Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations.

Authors:  Manhal Izzy; Brett E Fortune; Marina Serper; Nicole Bhave; Andrew deLemos; Juan F Gallegos-Orozco; Cesar Guerrero-Miranda; Shelley Hall; Matthew E Harinstein; Maria G Karas; Michael Kriss; Nicholas Lim; Maryse Palardy; Deirdre Sawinski; Emily Schonfeld; Anil Seetharam; Pratima Sharma; Jose Tallaj; Darshana M Dadhania; Lisa B VanWagner
Journal:  Am J Transplant       Date:  2022-03-31       Impact factor: 9.369

Review 3.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

Review 4.  Cardiac evaluation of the kidney or liver transplant candidate.

Authors:  Paul Emile Levy; Sadiya S Khan; Lisa B VanWagner
Journal:  Curr Opin Organ Transplant       Date:  2021-02-01       Impact factor: 2.640

5.  Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures.

Authors:  Amit K Mathur; Yu-Hui Chang; D Eric Steidley; Raymond L Heilman; Nabil Wasif; David Etzioni; Kunam S Reddy; Adyr A Moss
Journal:  BMC Nephrol       Date:  2019-05-28       Impact factor: 2.388

Review 6.  Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.

Authors:  Pranab M Barman; Lisa B VanWagner
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.298

7.  A Liver Transplant Patient on Everolimus Treatment Presented with Acute Anterior Myocardial Infarction: Does the Type of Drug-eluting Stent Matter?

Authors:  Muhammet Gürdoğan; Kenan Yalta; Mustafa Adem Yılmaztepe; Servet Altay; Ömer Ferudun Akkuş
Journal:  Balkan Med J       Date:  2019-12-27       Impact factor: 2.021

Review 8.  A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).

Authors:  Michael Urbich; Gary Globe; Krystallia Pantiri; Marieke Heisen; Craig Bennison; Heidi S Wirtz; Gian Luca Di Tanna
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.